Abarelix Evidence Guide
Abarelix (Plenaxis) is FDA-approved but was withdrawn from the US market due to a 3.7% anaphylaxis rate - a serious safety signal that terminated its commercial development. It established proof-of-concept for GnRH antagonism in prostate cancer, but degarelix (with a superior safety profile and active marketing) has replaced it as the GnRH antagonist of choice. Abarelix is a cautionary example, not a starting point.
Our Take
Abarelix (Plenaxis) is FDA-approved but was withdrawn from the US market due to a 3.7% anaphylaxis rate - a serious safety signal that terminated its commercial development. It established proof-of-concept for GnRH antagonism in prostate cancer, but degarelix (with a superior safety profile and active marketing) has replaced it as the GnRH antagonist of choice. Abarelix is a cautionary example, not a starting point.
- Best for
- Historical GnRH antagonist pharmacology reference only - not recommended for new research protocols
- Evidence grade
- Level A
- Confidence
- Moderate
- Starting point
- Not recommended due to anaphylaxis risk - degarelix is the appropriate alternative
Benefits and Evidence
- Rapid Testosterone Suppression: Level A, includes human evidence - Achieves castrate testosterone in >75% of patients by day 8 and >99% by day 29 without the initial testosterone flare seen with GnRH agonists. Critical for patients with symptomatic disease.
- Prostate Cancer Disease Control: Level A, includes human evidence - Maintains castrate testosterone levels comparable to leuprolide depot. PSA declines are equivalent to standard androgen deprivation therapy.
- Allergic Reaction Risk: Level A, includes human evidence - Immediate-onset systemic allergic reactions observed in approximately 3.7% of patients, including hypotension, syncope, and urticaria. This has significantly limited its clinical adoption.
Side Effects and Warnings
- Immediate-onset allergic reactions (3.7%)
- Hot flashes
- Sleep disturbances
- Breast enlargement
- Pain at injection site
- Constipation
- Peripheral edema
- Fatigue
Research Dosage References
- <strong>Intramuscular</strong> - 100 mg - Day 1, Day 15, Day 29, then every 4 weeks - Must be administered in healthcare setting with 30-minute post-injection observation due to allergic reaction risk. Supplied as powder for reconstitution.
Mechanism of Action
Abarelix achieves immediate gonadotropin suppression through competitive GnRH receptor antagonism: 1. Competitive blockade: Binds the pituitary GnRH receptor with high affinity, preventing endogenous GnRH from triggering LH and FSH release. 2. No flare effect: Unlike agonists, there is no initial surge in testosterone. LH, FSH, and testosterone begin declining immediately. 3. Rapid castration: Castrate testosterone levels (<50 ng/dL) achieved within 1 week in most patients, compared to 2-4 weeks with GnRH agonists. 4. Depot formulation: Intramuscular injection creates a depot at the injection site, providing sustained drug release over approximately 2 weeks per injection.
Legal Status
FDA-approved prescription medication (Plenaxis). Restricted distribution program. Available only in healthcare settings equipped for allergic reaction management. Not a controlled substance. No longer actively marketed in the US.
Primary Sources
- Abarelix depot versus leuprolide acetate for prostate cancer. Journal of Urology, 2002.
- Immediate-onset reactions to abarelix in prostate cancer patients. Urology, 2003.